Neuburgh Advisers’s Takeda Pharmaceutical TAK Stock Holding History

Neuburgh Advisers’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,096	Closed	-$143K	–	936
2019 Q2	$143K	Buy	+8,096	New	+$147K	﹤0.01%	750

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Neuburgh Advisers's TAK Position: Q3 2019 in Review

Neuburgh Advisers sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 8,096 shares — an estimated $143K sold.

Neuburgh Advisers first reported a position in TAK in Q2 2019 and held it in 1 quarter. The position peaked at $143K in Q2 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

Neuburgh Advisers reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
Neuburgh Advisers sold 8,096 Takeda Pharmaceutical shares in Q3 2019, an estimated $143K.
Neuburgh Advisers first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 1 quarter.
Neuburgh Advisers's Takeda Pharmaceutical position peaked at $143K in Q2 2019.
317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.